Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma

Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Jean Jacques Grob, M. M. Amonkar, S. Martin-Algarra, L. V. Demidov, V. Goodman, K. Grotzinger, P. Haney, E. Kämpgen, B. Karaszewska, C. Mauch, Jr H. Miller, M. Millward, B. Mirakhur, P. Rutkowski, V. Chiarion-Sileni, S. Swann, A. Hauschild

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P <0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P <0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.

Original languageEnglish
Article numbermdu154
Pages (from-to)1428-1436
Number of pages9
JournalAnnals of Oncology
Volume25
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Dacarbazine
Melanoma
Quality of Life
Nausea
Vomiting
Sleep Initiation and Maintenance Disorders
Appetite
Disease-Free Survival
Fatigue
Pain
Insurance Benefits
Dyspnea
dabrafenib
Diarrhea
Confidence Intervals
Neoplasms

Keywords

  • BRAF
  • Chemotherapy
  • Dabrafenib
  • Melanoma
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Grob, J. J., Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., ... Hauschild, A. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology, 25(7), 1428-1436. [mdu154]. https://doi.org/10.1093/annonc/mdu154

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma : Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. / Grob, Jean Jacques; Amonkar, M. M.; Martin-Algarra, S.; Demidov, L. V.; Goodman, V.; Grotzinger, K.; Haney, P.; Kämpgen, E.; Karaszewska, B.; Mauch, C.; Miller, Jr H.; Millward, M.; Mirakhur, B.; Rutkowski, P.; Chiarion-Sileni, V.; Swann, S.; Hauschild, A.

In: Annals of Oncology, Vol. 25, No. 7, mdu154, 2014, p. 1428-1436.

Research output: Contribution to journalArticle

Grob, JJ, Amonkar, MM, Martin-Algarra, S, Demidov, LV, Goodman, V, Grotzinger, K, Haney, P, Kämpgen, E, Karaszewska, B, Mauch, C, Miller, JH, Millward, M, Mirakhur, B, Rutkowski, P, Chiarion-Sileni, V, Swann, S & Hauschild, A 2014, 'Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine', Annals of Oncology, vol. 25, no. 7, mdu154, pp. 1428-1436. https://doi.org/10.1093/annonc/mdu154
Grob, Jean Jacques ; Amonkar, M. M. ; Martin-Algarra, S. ; Demidov, L. V. ; Goodman, V. ; Grotzinger, K. ; Haney, P. ; Kämpgen, E. ; Karaszewska, B. ; Mauch, C. ; Miller, Jr H. ; Millward, M. ; Mirakhur, B. ; Rutkowski, P. ; Chiarion-Sileni, V. ; Swann, S. ; Hauschild, A. / Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma : Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. In: Annals of Oncology. 2014 ; Vol. 25, No. 7. pp. 1428-1436.
@article{254e3fb8f6ae4fa989ce6a220592afba,
title = "Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine",
abstract = "Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95{\%} confidence interval 0.18-0.53; P <0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P <0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.",
keywords = "BRAF, Chemotherapy, Dabrafenib, Melanoma, Quality of life",
author = "Grob, {Jean Jacques} and Amonkar, {M. M.} and S. Martin-Algarra and Demidov, {L. V.} and V. Goodman and K. Grotzinger and P. Haney and E. K{\"a}mpgen and B. Karaszewska and C. Mauch and Miller, {Jr H.} and M. Millward and B. Mirakhur and P. Rutkowski and V. Chiarion-Sileni and S. Swann and A. Hauschild",
year = "2014",
doi = "10.1093/annonc/mdu154",
language = "English",
volume = "25",
pages = "1428--1436",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma

T2 - Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

AU - Grob, Jean Jacques

AU - Amonkar, M. M.

AU - Martin-Algarra, S.

AU - Demidov, L. V.

AU - Goodman, V.

AU - Grotzinger, K.

AU - Haney, P.

AU - Kämpgen, E.

AU - Karaszewska, B.

AU - Mauch, C.

AU - Miller, Jr H.

AU - Millward, M.

AU - Mirakhur, B.

AU - Rutkowski, P.

AU - Chiarion-Sileni, V.

AU - Swann, S.

AU - Hauschild, A.

PY - 2014

Y1 - 2014

N2 - Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P <0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P <0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.

AB - Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P <0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. Methods: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. Results: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P <0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. Conclusions: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient.

KW - BRAF

KW - Chemotherapy

KW - Dabrafenib

KW - Melanoma

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84903741191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903741191&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdu154

DO - 10.1093/annonc/mdu154

M3 - Article

VL - 25

SP - 1428

EP - 1436

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

M1 - mdu154

ER -